Actively Recruiting
Global Study of Sequential T-DXd-Based Therapy Followed by Palbociclib, Endocrine Therapy, and Dual HER2 Blockade in First-Line HER2HR Advanced Breast Cancer with T-DXd Retreatment
Led by Daiichi Sankyo · Updated on 2026-10-16
200
Participants Needed
5
Research Sites
7 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a sequential treatment strategy for adults with HER2-positive and hormone receptor-positive advanced or metastatic breast cancer. The goal is to maximize disease control, optimize tolerability, and preserve trastuzumab deruxtecan T-DXd as a future treatment option. This global, open-label phase 3b trial assesses the effectiveness and safety of this approach, as well as quality-of-life outcomes. The treatment begins with upfront therapy combining T-DXd and pertuzumab given intravenously every three weeks for 18 to 24 cycles. Then participants transition to maintenance therapy with trastuzumab, pertuzumab, endocrine therapy, and oral palbociclib. If the disease progresses during maintenance, participants may receive retreatment with T-DXd monotherapy every three weeks. Dose reductions during upfront treatment will be maintained. Participants will be monitored through regular imaging and clinical assessments to measure progression-free survival and response rates up to 24 months. Quality-of-life questionnaires will track changes during treatment phases. Safety will be observed by recording adverse events during all treatment periods, including retreatment. The entire study spans several years, with follow-up to evaluate long-term outcomes and tolerability.
CONDITIONS
Brief Title
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Research Team
C
Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here